Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

• Published in: The Journal of urology Vol. 129; no. 1; p. 51
• Main Authors: Worgul, T J, Santen, R J, Samojlik, E, Veldhuis, J D, Lipton, A, Harvey, H A, Drago, J R, Rohner, T J
• Format: Journal Article
• Language: English
• Published: United States 01-01-1983
• Subjects: Adenocarcinoma - blood; Adenocarcinoma - drug therapy; Aged; Aminoglutethimide - adverse effects; Aminoglutethimide - therapeutic use; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Dihydrotestosterone - blood; Drug Therapy, Combination; Humans; Hydrocortisone - therapeutic use; Male; Middle Aged; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Testosterone - blood
• ISSN: 0022-5347
• DOI: 10.1016/S0022-5347(17)51916-3

Treatment of male patients with advanced prostatic carcinoma and disease progression after initial endocrine therapy frequently is unsatisfactory. However, approximately 20 per cent of these patients respond to surgical adrenalectomy or hypophysectomy, indicating continued hormonal responsiveness. A total of 25 previously castrated men with stage D carcinoma received 1,000 mg. aminoglutethimide and 40 mg. hydrocortisone daily. The patients were evaluated using the criteria of the National Prostatic Cancer Project. One patient has had a complete response and is in remission after 275 weeks of therapy. A partial response was noted in 4 patients, while the disease was objectively stable in 6. Pre-treatment testosterone and dihydrotestosterone levels were measured in 9 of 25 patients and were significantly reduced statistically during aminoglutethimide therapy (p less than 0.01). Response and drug toxicity are discussed.